

GLAXOSMITHKLINE PLC
Form 6-K
August 04, 2008

FORM 6-K

**SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549**

Report of Foreign Issuer

**Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934**

For period ending August 04, 2008

GlaxoSmithKline plc
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)

Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F x Form 40-F

--

Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.

Yes No x

--

Notification of Transactions of Directors, Persons Discharging Managerial Responsibility or Connected Persons

Following a re-valuation of the cash element of the notional investment held within the US Retirement Savings Plan ("The Plan"), which is notionally held in GSK Ordinary Share ADRs, the Administrators of the Plan notified GlaxoSmithKline plc and the under-mentioned

person

s on 4

August

2008

of a

n increase in the notional allocation of Ordinary Share ADRs on

31 July

2008

at a price of \$

46.56

per ADR:-

Dr M M Slaoui	3
---------------	---

Mrs C Bruck Slaoui	2
--------------------	---

Mr C Viehbacher	6
-----------------	---

Mr E J Gray	16
-------------	----

Mr W C Louv	7
-------------	---

Dr D Pulman	18
-------------	----

Mr S M Werner	8
---------------	---

Th

i

s notification

relates to a

transaction notified in accordance with

Disclosure

and Transparency Rule 3.1.4R(1)(a

).

S M Bicknell

Company Secretary

4 August

2008

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc
(Registrant)

Date: August 04, 2008

By: VICTORIA WHYTE

Victoria Whyte

Authorised Signatory for and on
behalf of GlaxoSmithKline plc